 AIM ImmunoTech Inc said it has submitted an Investigational New Drug application IND and an accompanying application for Fast Track status with the US Food and Drug Administration FDA for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The company said the planned AMP-270 clinical trial of around 250 subjects will be a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen when added to SOC standard of care versus SOC alone for subjects with advanced pancreatic carcinoma recently treated with FOLFIRINOX chemotherapy regimen. 